...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.
【24h】

Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project.

机译:外周T细胞淋巴瘤,未另作说明:国际外周T细胞淋巴瘤项目报告340例。

获取原文
获取原文并翻译 | 示例

摘要

The International Peripheral T-cell Lymphoma Project is a collaborative effort to better understand peripheral T-cell lymphoma (PTCL). A total of 22 institutions submitted clinical and pathologic material on 1314 cases. One objective was to analyze the clinical and pathologic features of 340 cases of PTCL, not otherwise specified. The median age of the patients was 60 years, and the majority (69%) presented with advanced stage disease. Most patients (87%) presented with nodal disease, but extranodal disease was present in 62%. The 5-year overall survival was 32%, and the 5-year failure-free survival was only 20%. The majority of patients (80%) were treated with combination chemotherapy that included an anthracycline, but there was no survival advantage. The International Prognostic Index (IPI) was predictive of both overall survival and failure-free survival (P < .001). Multivariate analysis of clinical and pathologic prognostic factors, respectively, when controlling for the IPI, identified bulky disease (>/= 10 cm), thrombocytopenia (< 150 x 10(9)/L), and a high number of transformed tumor cells (> 70%) as adverse predictors of survival, but only the latter was significant in final analysis. Thus, the IPI and a single pathologic feature could be used to stratify patients with PTCL-not otherwise specified for novel and risk-adapted therapies.
机译:国际外周T细胞淋巴瘤项目是一项旨在更好地了解外周T细胞淋巴瘤(PTCL)的合作努力。共有22家机构提交了1314例病例的临床和病理资料。目的是分析340例PTCL(未另作说明)的临床和病理特征。患者的中位年龄为60岁,大多数(69%)患有晚期疾病。大多数患者(87%)出现淋巴结病,但有62%存在淋巴结外病。 5年总生存率为32%,而5年无故障生存率仅为20%。大多数患者(80%)接受了包括蒽环类药物的联合化疗,但没有生存优势。国际预后指数(IPI)可预测总体生存期和无失败生存期(P <.001)。在控制IPI时,分别对临床和病理预后因素进行多变量分析,确定出大块疾病(> / = 10 cm),血小板减少症(<150 x 10(9)/ L)和大量转化的肿瘤细胞( > 70%)作为生存的不良预测指标,但只有后者在最终分析中具有重要意义。因此,IPI和单一病理学特征可用于对PTCL患者进行分层-除非另有说明,否则该患者不能用于新型且适应风险的疗法。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号